ST. LOUIS, MO // March 10, 2016 // STLToday.com — We at St. Alexius NewStart, are excited to share that the U.S. Food and Drug Administration has approved ORBERA™ to assist adult patients suffering from obesity – with a body mass index (BMI) of 30 to 40 – in losing and maintaining weight. ORBERA™ is a safe and effective weight loss solution with 20 years of global experience and real world results. More than 220,000 ORBERA™ balloons distributed worldwide in over 80 countries. St. Alexius NewStart will be one of the first in the country to offer this new tool in helping people achieve their weight loss goals.
The ORBERA™ balloon is part of the ORBERA™ Managed Weight Loss System, a comprehensive, non-surgical two-part program that includes a balloon filling space in a patient’s stomach to reinforce proper portion control. Data on ORBERA™ collected in the U.S. clinical trial has shown that the average person lost 3.1 times the weight as compared with diet and exercise alone within six months.
St. Alexius NewStart recognizes that obesity is a chronic disease and we are pleased to be able to offer new, minimally invasive solutions, like ORBERA™, to help transform the lives of patients before their disease progresses and requires more invasive treatment. For additional information regarding ORBERA™, please visit orbera.com and orbera.com/dfu. For more information on ORBERA™ at St. Alexius NewStart, please visit StAlexiusNewStart.com/Orbera.